2 active not recruiting, 2 recruiting, 2 unknown, 1 not yet recruiting. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 2, Recruiting 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Neoadjuvant Treatment: new trials by email Literature Review of Neoadjuvant Treatment trials Research Report on Neoadjuvant Treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery Zanzalintinib - Neoadjuvant Treatment, Thyroid Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 45 | 2025-07-22 | 2026-11-05 |
| Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib, Esophagectomy, Collecting samples from participant - Esophageal Squamous Cell Carcinoma, Neoadjuvant Treatment | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 35 | 2024-08-08 | 2025-12-02 |
| Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer Anlotinib+Capeox, Capeox - Neoadjuvant Treatment, Rectal Cancer | Phase 2 | Withdrawn | Shanghai Minimally Invasive Surgery Center | 2023-11-01 | 2021-09-28 | |
| Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy Bevacizumab+mFOLFOX6 - Neoadjuvant Treatment, Rectal Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Minimally Invasive Surgery Center | 20 | 2022-11-01 | 2024-03-07 |
| The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC Tislelizumab, Low-dose radiotherapy - Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment | Phase 2 | Active not recruiting | Fifth Affiliated Hospital, Sun Yat-Sen University | 25 | 2022-03-09 | 2026-09-09 |
| Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma Lenvatinib, Pembrolizumab - Mucosal Melanoma, Neoadjuvant Treatment | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 26 | 2020-12-30 | 2020-11-13 |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Olaparib, Platinum-based Chemotherapy - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Active not recruiting | University Health Network, Toronto | 71 | 2016-07-19 | 2026-06-23 |
| Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer Cetuximab, Irinotecan, Capecitabine - Rectal Neoplasms, Neoadjuvant Treatment | Phase 2 | Unknown | National Cancer Center, Korea | 40 | 2006-05-01 | 2007-07-25 |
Rectal Neoplasms (3) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Thyroid Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Rectal Diseases (3) · Carcinoma (2) · Carcinoma, Squamous Cell (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2)
Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Esophagectomy (1) · Irinotecan (1) · Platinum Compounds (1) · Radiotherapy (1) · apatinib (1) · lenvatinib (1) · olaparib (1) · pembrolizumab (1) · tislelizumab (1)
Shanghai Minimally Invasive Surgery Center (2) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · M.D. Anderson Cancer Center (1) · National Cancer Center, Korea (1) · Peking University Cancer Hospital & Institute (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University Health Network, Toronto (1)
China (4) · Canada (1) · New Zealand (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)
Amit Oza, M.D. (1) · Jun Guo, MD (1) · Kyung Hae Jung, M.D.Ph.D (1) · Mark Zafereo, MD (1)